Germany-based biotechnology firm specializing in the search for active agents and ingredients in naturally-occurring substances for use in the pharmaceutical, cosmetics, and food industries.Biotechnology Research And Information Network AG (BRAIN), the Germany-based company engaged in the discovery and development of novel natural bioactive compounds, microbial producer strains, proprietary enzymes, designer microorganisms, and biocatalysts for various applications, has acquired a 57.7% stake in AnalytiCon Discovery GmbH, the Germany-based biotechnology firm specializing in the search for active agents in naturally-occurring substances, from Sobera Capital GmbH and BC Brandenburg Capital GmbH, both Germany-based private equity and venture capital firms, for an undisclosed consideration.
The acquisition will allow BRAIN to consolidate its position in the biotech industry and to expand its range of natural products, microorganisms, plants, and gene libraries. Aside from BRAIN, the only additional shareholders of the target company will be the management and key employees of AnalytiCon.
BRAIN and AnalytiCon have been working together as a part of the strategic alliance NatLife 2020 since February 2013. BC Brandenburg has been invested in the target through its KBB Kapitalbeteiligungsgesellschaft fund ever since AnalytiCon’s establishment in 2000.
Sources:
AnalytiCon Discovery GmbH press release, 03 July 2014
Biotechnology Research And Information Network AG press release, 03 July 2014
VR Corporate Finance GmbH press release, 03 July 2014
DZ BANK AG
Advised in the sale of
AnalytiCon Discovery GmbH (57.7% Stake)
to